![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
NW DiTullio, L Cieslinski, WD Matthews and B Storer
Clonidine induced a dose-dependent hyperglycemic response in fed rats, a minimal hyperglycemic response in 48-hr fasted rats and had no effect on blood glucose in 16-hr fasted, streptozotocin-diabetic rats. At a dose of 0.1 mg/kg, there was an equivalent hyperglycemic response in fed rats whether clonidine was administered orally, i.v. or i.p. A hyperglycemic effect was also observed with the central and peripheral alpha-2 adrenoceptor agonist, guanabenz (0.1 mg/kg i.v.). In contrast, 2-(3-4-dihydroxyphenylimino) imidazoline, an alpha-2 agonist which does not penetrate into the central nervous system, caused a lowering of blood glucose at the same dose. The hyperglycemic response induced by clonidine was partially inhibited by the selective alpha-2 antagonists, yohimbine and rauwolscine, and the nonselective alpha antagonist, phentolamine. The hyperglycemic response induced by clonidine was not affected by the selective alpha-1 adrenoceptor antagonists, prazosin or corynanthine. Methoxamine, an alpha-1 agonist, had no effect on clonidine-induced hyperglycemia. The hyperglycemic response to clonidine was partially inhibited by 3-mercaptopicolinic acid, an inhibitor of gluconeogenesis, but was not affected by pretreatment with the H2-histamine receptor antagonist, metiamide, the prostaglandin syntheses inhibitor, idomethacin, or the beta adrenoceptor antagonist, propranolol. These results suggest that 1) the hyperglycemic response induced by clonidine and other alpha-2 adrenergic agonists is mediated by alpha-2 adrenergic receptors located within the central nervous system and 2) clonidine-induced hyperglycemia is effected, in part, by enhanced gluconeogenesis.
This article has been cited by other articles:
|
|
 |
|
  F. Horio, S. Teradaira, T. Imamura, R. V. P Anunciado, M. Kobayashi, T. Namikawa, and I. Niki The HND mouse, a nonobese model of type 2 diabetes mellitus with impaired insulin secretion Eur. J. Endocrinol., December 1, 2005; 153(6): 971 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Davani, N. Portwood, G. Bryzgalova, M. K. Reimer, T. Heiden, C.-G. Ostenson, S. Okret, B. Ahren, S. Efendic, and A. Khan Aged Transgenic Mice With Increased Glucocorticoid Sensitivity in Pancreatic {beta}-Cells Develop Diabetes Diabetes, February 1, 2004; 53(90001): S51 - 59. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. A. Velliquette and P. Ernsberger The Role of I1-Imidazoline and {alpha}2-Adrenergic Receptors in the Modulation of Glucose Metabolism in the Spontaneously Hypertensive Obese Rat Model of Metabolic Syndrome X J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 646 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lattermann, T. Schricker, M. Georgieff, and M. Schreiber Low dose clonidine premedication accentuates the hyperglycemic response to surgery : [Une premedication avec une faible dose de clonidine accentue la reaction hyperglycemique a la chirurgie] Can J Anesth, September 1, 2001; 48(8): 755 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ernsberger, T. Ishizuka, S. Liu, C. J. Farrell, D. Bedol, R. J. Koletsky, and J. E. Friedman Mechanisms of Antihyperglycemic Effects of Moxonidine in the Obese Spontaneously Hypertensive Koletsky Rat (SHROB) J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 139 - 147. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. J. Henriksen, S. Jacob, D. L. Fogt, E. B. Youngblood, and J. Godicke Antihypertensive Agent Moxonidine Enhances Muscle Glucose Transport in Insulin-Resistant Rats Hypertension, December 1, 1997; 30(6): 1560 - 1565. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
